- Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol. 2014;3(4):156–168. doi:https://doi.org/10.5527/wjn.v3.i4.156.
- Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41–48. doi:https://doi.org/10.2174/1874192401105010041.
- Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 1997;8(12):1889–1898.
- Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793–808. doi:https://doi.org/10.1046/j.1523-1755.2003.00803.x.
- Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. JASN. 2007;18(1):293–303. doi:https://doi.org/10.1681/ASN.2006070795.
- Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451–459. doi:https://doi.org/10.1001/jama.291.4.451.
- Cho EY, Myoung C, Park HS, et al. Efficacy of statin treatment in early-stage chronic kidney disease. PLoS One. 2017;12(1):e0170017. doi:https://doi.org/10.1371/journal.pone.0170017.
- Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248. doi:https://doi.org/10.1056/NEJMoa043545.
- Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407. doi:https://doi.org/10.1056/NEJMoa0810177.
- Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192. doi:https://doi.org/10.1016/S0140-6736(11)60739-3.
- Jung J, Bae GH, Kang M, Kim SW, Lee DH. Statins and all-cause mortality in patients undergoing hemodialysis. J Am Heart Assoc. 2020;9(5):e014840. doi:https://doi.org/10.1161/JAHA.119.014840.
Usefulness of statins in end-stage renal disease
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.